Since Amgen Inc. and Novartis AG are likely to have the first CGRP inhibitor on the market with Aimovig (erenumab), the partners will have an important opportunity to set the pricing and reimbursement tone for the class of migraine therapies, which ultimately will determine whether Aimovig lives up to the hype or becomes a PCSK9-like disappointment.
Amgen CEO Bob Bradway said on the company’s April 24 first quarter earnings call that the company expects to launch Aimovig for the prevention of migraine headaches during the second quarter,
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?